TMSP(SH:600671)2019-08-27 16:00Financial Performance - Operating income for the period was CNY 75,708,330.55, representing a decline of 16.23% year-on-year[6] - The net profit attributable to shareholders of the listed company was CNY -1,874,831.33, showing a slight improvement from CNY -1,882,756.79 in the previous year[6] - The weighted average return on net assets was -3.27%, compared to -2.85% in the same period last year[6] - Basic and diluted earnings per share were both CNY -0.02, unchanged from the previous year[6] - The company reported a net profit attributable to shareholders of -¥1,874,800, with a warning that cumulative net profit for the year may be a loss due to a significant decrease in non-recurring gains[18] - Net profit for Q1 2019 was a loss of CNY 1,005,525.92, an improvement from a loss of CNY 1,607,169.74 in Q1 2018[29] - The total comprehensive income for Q1 2019 was CNY 132,534.73, compared to a net loss of CNY -2,721,121.03 in the same period last year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 462,642,130.95, a decrease of 0.31% compared to the end of the previous year[6] - Total current assets decreased to CNY 215,159,084.73 from CNY 217,226,711.26, a decline of approximately 0.49%[22] - Total liabilities decreased marginally to CNY 372,089,270.77 from CNY 372,514,593.90, a reduction of about 0.11%[23] - Total non-current assets increased to CNY 247,483,046.22 from CNY 246,846,268.74, a growth of about 0.26%[22] - Total equity decreased to CNY 90,552,860.18 from CNY 91,558,386.10, a decline of about 1.10%[23] - Long-term borrowings increased by 100% to ¥13,000,000, primarily due to an increase in bank loans by the subsidiary Huangshan Mint[14] Cash Flow - Net cash flow from operating activities increased by 13.05% to CNY 38,750,738.27 compared to the same period last year[6] - The company's cash and cash equivalents decreased by 24.87% to ¥65,214,616.16, primarily due to payments for various renovation projects and bank loan repayments[13] - The net cash flow from operating activities was CNY 38,750,738.27, an increase from CNY 34,276,082.11 in Q1 2018, reflecting a growth of approximately 13.6%[33] - The company reported a net cash outflow from financing activities of CNY -59,559,194.87, compared to a smaller outflow of CNY -6,061,952.31 in the previous year[34] - The company’s net cash flow from investing activities was CNY -932,586.70, a significant decline from CNY 8,198,076.72 in Q1 2018[33] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,680[10] - The largest shareholder, Changcheng Film and Television Culture Enterprise Group Co., Ltd., held 27.25% of the shares, totaling 33,181,813 shares[10] Operational Developments - The company has not disclosed any new product developments or market expansion strategies in this report[6] - The company is in the process of relocating its production facility in Lin'an, which is expected to have a significant impact on operations, with a compensation amount of ¥210,918,492 for the property[16] - The company has signed a technical development contract for the consistency evaluation of its main product, Amoxicillin and Clavulanate Potassium Tablets, aiming to complete the evaluation by the end of 2021[16] - The company plans to expand its investment in the health industry by contributing ¥14,000,000 to establish a health industry park in Xishuangbanna, holding a 9.33% stake[15] Accounts Receivable and Inventory - Accounts receivable increased by 27.91% to ¥72,805,398.80, with a significant rise in accounts receivable from the subsidiary Huangshan Mint contributing ¥17,940,000[13] - Inventory rose slightly to CNY 69,123,324.46 from CNY 68,761,605.62, an increase of approximately 0.53%[21]